Japan

Benefits of long-term Tysabri seen in RRMS patients in Japan: Study

Tysabri (natalizumab) significantly reduced the development of brain lesions on MRI scans in Japanese people with relapsing-remitting multiple sclerosis (RRMS), according to a new study. The therapy also eased or stabilized disability levels in most patients after five years of treatment, and significantly reduced the annual rate of…

Long-term Treatment with Gilenya Found to Limit Lesions, Relapses in Japanese MS Patients

Continuous treatment with Gilenya (fingolimod)Ā helps limit relapses and detectable lesions in multiple sclerosis (MS) patients, according to a three-year, follow-upĀ studyĀ in Japan. The results confirmĀ the findings of trials conducted in predominantly Caucasian populations. The findings were reported in the study, ā€œLong-term efficacy and safety of fingolimod in…

New Research Center at UC San Diego to Focus on Microbiome and Immunology

TheĀ University of California (UC) San Diego School of Medicine and Chiba University School of Medicine, Japan, are working togetherĀ to establishĀ a newĀ center forĀ immunology research, with a particular focusĀ on the microbiome and mucosal immune responses that are knownĀ to play a crucial role in a variety of diseases, including multiple sclerosis (MS). ā€œThis…

Relapsing Multiple Sclerosis Treatment Now Available in Japan

Takeda Pharmaceutical, a pharmaceutical company based in Osaka, Japan, recently announcedĀ that a widely approved drug treatment forĀ the prevention of relapses in multiple sclerosis (MS)Ā is nowĀ available in Japan as well. Copaxone,Ā (glatiramer acetate; 20 mg daily subcutaneous injection), developed by Teva Pharmaceuticals, is an immunomodulatory drug designed toĀ act as…

Teva’s COPAXONE Approved in Japan for the Prevention of Relapse Remitting Multiple Sclerosis

Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions, recently announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the once per day 20 mg injection of COPAXONEĀ®Ā as prophylaxis for relapses in multiple sclerosis (MS). Glatiramer acetate, the active…